Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer

Kephera Diagnostics receives Phase II contract from the National Cancer Institute for a test for liver fluke, an exotic parasite linked to bile duct cancer Framingham, MA – October 20, 2021.  Kephera Diagnostics has been awarded a $1,999,961 million Phase II Small Business Innovative Research (SBIR) contract by the National Cancer Institute, an agency of…

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease

NIAID awards Phase I contract to Kephera Diagnostics for the development of a new test for Chagas disease National Institutes of Health awards contract to develop a test-of-cure for Chagas disease Framingham, MA – September 23, 2021.  The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH),…

Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test

Kephera Diagnostics receives $417,074 grant award from the Massachusetts Life Sciences Center to accelerate development of its rapid COVID-19 Antigen Test Baker-Polito Administration and Massachusetts Life Sciences Center Announce More Than $1.5 Million to Support Development and Acceleration of Coronavirus Testing Solutions The full text of this announcement can be viewed at https://www.mass.gov/news/baker-polito-administration-and-massachusetts-life-sciences-center-announce-more-than-15 BOSTON —…